[FUTURE THERAPIES FOR CYSTIC FIBROSIS].
Current cystic fibrosis treatment is symptomatic and has greatly increased life expectancy over the last decades. However, mean age of death is still 29-years-old. Innovative therapeutic molecules aiming at restoring CFTR function are developed. Ivacaftor is the first medicine approved in 2012 for the 3% of patients worldwide carrying the rare CFTR mutation called G5510. Ivacafter is associated with a sustained improvement in respiratory function and a decreased frequency of pulmonary exacerbations. Other pharmacotherapies are being developed that aim at correcting other CFTR defects due to other CFTR mutations, especially the most frequent F508del mutation.